# VOLUME 34 1989

## SUBJECT INDEX


A-65186, 779
[$^3$H]ACh binding, HCh-3 binding, 129
ACh content, 129
AChE inhibitor, 129
Abuse liability, 303
Acetylcholine, 207, 261
Acetylcholinesterase, 805
N-acetylneuraminic acid, 209
Acetyl-salicyclic acid, 325
Active avoidance learning, 805
Acute opioid dependence, 705
Adenosine agonist, 507
S-Adenosyl-L-methionine (SAM), 395
Adenylate cyclase, 139
Adjunctive drinking, 591
Adrenalectomy and nicotine lethality, 559
Adverse side-effects, 685
Affective disorders, 207
Aged rats, 805
Aggression, 247
Aggressive, 65
Akathisia, 759
Alarm pheromone, 213
Alcohol, 201, 591
Alcohol drinking, 381
Alcohol intake, 201
Alcohol-preferring rats, 381
Alloxan, 511
Alpha-1 receptors, 89
Alpha-2 receptors, 89
N-Allylnormetazocine, 405
Ambivalent behaviors, 361
Amino acid neurotransmitters, 905
Amino acids, 107, 829
1-Aminocyclopropanecarboxylic acid, 313
Amnesia, 439
Amotivational syndrome, 871
Amphetamine, 165, 289, 545, 739, 863, 923
*d*-Amphetamine, 65, 187, 297, 609, 791
(+)-Amphetamine, 465
Amphibians, 753
Analgesia, 83, 317, 413, 425, 497, 911
Angiotensin II, 201
Angiotensin converting enzyme inhibitor, 685
Animal model of depression, 691
Anorexia, 17, 317, 717, 797
Anterior nucleus accumbens, 157
Anticholinergic, 303
Antihypertensive agents, 685
Antinociception, 511
Antipsychotic drug, 759
Antitussive drugs, 595
Anxiety, 931
Anxiogenic drug, 785
Anxiolytic agents, 293
Anxiolytic response, 1
Anxiolytics, 313
Apomorphine, 59, 345, 545, 673, 915, 923
Appetite, 433
Atropine, 303
Attention, 823
Aversive behavior, 769
Avoidance, 585

BALB mouse, 165
Baboons, 685
Baclofen, 491
Barbiturate, 399
Barbiturate anesthesia, 727
Bay-K-8644, 325
Behavior, 181, 303, 337, 473, 863
Behavioral alterations, 229
Behavioral effects, 609
Behavioral pharmacology, 297, 609
Behavioral sensitization, 345
Behavioral tests, 839
Benzodiazepine, 37, 399, 585, 733, 839
Benzodiazepine receptors, 711
Beta-adrenergic receptor, 603
Beta-adrenoceptors, 247
Biochemistry, 473
Biogenic amines, 223
Blood glucose, 791
Blood $\Delta^9$-THC and COHb saturation from marihuana smoke, 521
Blood pressure, 349, 685
Body rotation, 317
Body temperature, 375
Body temperature by radio telemetry, 241
Brain, 355
Brain 5-HT receptors, 275, 283
Brain areas, 341
Brain dopamine, 577
Brain liquification, 77
Brain self-stimulation, 23, 785
Brain serotonin, 577
Brain slices, 571
Bremazocine, 753
Brightness discrimination, 209
Buspirone, 349
Butorphanol, 847

cAMP, 665
CBA/Ca mice, 255
C × B recombinant inbred strains, 733
CCK, 779
CCKA receptors, 157
CCK-8, 95, 779
CGS 8216, 585
ChAT, 129
CL218872, 711
CPP, 739
C3H mouse, 165
C57 mice, 165, 331
C57BL/6J mice, 241
Caerulein, 95
Cafeteria rat, 341, 577
Caffeine, 483, 565
Calcium, 73
Calcium gluconate, 73
Carbohydrate, 829
β-Carboline, 733
β-Carboline-3-carboxylate-*t*-butyl ester, 37
Cardiovascular, 565, 631
Cardiovascular effects, 405, 697
Catechol estrogens, 459
Catecholamines, 349, 565
Catheterized, 349
Cathinone, 289
Caudate nucleus, 367
Central morphine analgesia, 119
Chicken embryos, 705
Chicks, 439
Chlordiazepoxide, 313, 711, 931
Chlordiazepoxide dependence, 839
7-Chlorokynurenic acid, 313
Chloroquine, 77
Chlorpromazine, 1, 585
Choice, 297
Cholecystokinin, 779
Cholecystokinin octapeptide, 157, 387
Cholecystokinin octapeptide unsulfated, 157
Choline acetyltransferase, 805
Cholinergic, 207, 261
Cholinergic supersensitivity, 691
Cigarettes, 565
Cinnarizine, 325
Circadian, 533
Circadian rhythms, 465
Circumventricular organ, 201
Cleft palate, 77
Climbing, 95
Clonidine, 413, 433
Clonidine aggressive behavior, 503
Cocaine, 165, 289, 655, 697, 887, 899
Coffee, 565
Cognitive enhancement, 649
Cognitive tasks, 173
Cold-water swim, 83
Color discrimination, 685
Computer, 919
Concurrent schedule, 297
Conditioned drug effects, 663
Conditioned position responding, 29
Conditioning, 59, 655
Continuous cold-water swims, 511
Control of ventilation, 681
Corticosterone, 247
Corticotropin-releasing factor, 517
Cortisol, 747
Cough reflex, 595
Cumulative dose-effect curves, 855

$D_1$, 43
$D_1$-agonist, 367
$D_2$, 43
$D_2$-antagonist, 355, 367
D1 receptors, 337, 923
D2 receptor, 453, 923
DBA mouse, 165
DFP, 473
DNA, 77
DSLET, 577
Delayed matching to sample, 29
Depression, 207
Desmethylimipramine, 915
Development, 367, 721, 727
Developmental neurotransmitters, 229
Diabetes, 255, 511
Diazepam, 1, 23, 29, 609, 769
Dichloromethane, 619
Discrete trial, 297
Discriminative stimulus properties, 23
Diterpine, 503

Dogs, decerebrated, 405
Dopamine, 59, 95, 113, 165, 289, 337, 341, 345, 367, 453, 571, 727
Dopamine antagonists, 43
Dopamine development, 545
Dopamine $D_1$ receptor, 17
Dopamine D1/D2 receptors, 465
Dopamine receptors, 139, 721
Dorsal immobility response, 459
Dose response, 697
Down regulation, 247
Drug, 303
Drug abuse, 609
Drug discrimination, 289, 337, 429, 571, 641, 711
Drug effects, 29
Drug history, 149
Drug self-administration, 149
Drug-induced compensatory learning, 855
Dynorphin (1–13), 577
Dyskinesia, 95, 193, 759
Dystonia, 759

EEG, 619, 631
EGTA, 73
*E. coli* endotoxin, 325
Eating, 631
Electroencephalogram, 507
Elevated plus-maze, 931
Emotionality, 157, 197, 361
Enalapril maleate, 685
Endogenous opioids, 681
β-Endorphin, 577
Energy expenditure, 765
Energy substrate utilisation, 765
Enrichment, 487
Entactogens, 571
Epinephrine, 247
Escape task, 439
Estradiol, 89, 459
Estrous phases, 119
Ethanol, 77, 201, 247, 321, 331, 399, 487, 585, 855, 905
Ethanol antagonism, 399
Ethanol lethality, 375
Ethanol stimulation, 331
Ethylketazocine, 405
Etonitazene, 419
Event-related potentials, 631
Excitatory amino acids, 101
Excitotoxic lesions, 139
Exogenous gangliosides, 209
Expectancy, 149
Exploration, 157
Exploratory behavior, 517
Exteroceptive stimulus control, 641
Extinction, 585, 591

FMRF-amide, 341
FR-40 disruption, 275, 283
FSL rats, 691
Fasting, 791
Feeding, 433, 911
Feeding behavior, 539
Fenoldopam, 17
Fentanyl, 419
Fetal striatal tissue grafts, 139
Fetus, 77
Fixed interval:15 second schedule, 785
Fixed ratio:15 schedule, 785
Flumazenil (Ro 15-1788), 399
Fluoxetine, 381
Food deprivation, 791
Food intake, 341, 577, 717, 797
Forced inhalation of marihuana smoke, 521
Forskolin, 139, 665
Frontal cortex, 805

GABA, 237, 905
$GABA_A$ receptors, 237
$GABA_B$ receptors, 237
GABA motor impairment, 399
Galanthamine, 129
Gender differences, 119
Genetic analysis, 733
Genetics, 905
Glucose, 631
Glycine, 313, 491, 823
Glycine receptor, 649
Gonadectomy, 119
Guinea pig, 89
Guinea pig ileum assay, 527

HPA axis, 747
HPLC, 545
5-HT agonist, 275, 283
5-HT receptors, 603, 717
5-HT-dependent behavior, 603
$5\text{-}HT_{1A}$ and $5\text{-}HT_{1B}$ receptor subtypes, 811
$5\text{-}HT_{1A}$ receptors, 927
$5\text{-}HT_3$ receptor antagonist, 769
Haloperidol, 95, 113, 345, 721, 727
Hamster, 387
Heart rate, 349
Hepatomegaly, 77
Hexamethonium, 817
Hexamethonium prevention of nicotine lethality, 559
High-affinity choline uptake, 553
Hippocampus, 553, 805
Hot-plate test, 497
Human behavioral pharmacology, 173
Human speech, 609
Human study, 303
Humans, 65, 297, 697, 791, 871
6-Hydroxydopamine, 367, 413, 663
5-Hydroxytryptamine (5-HT), 165, 603, 717, 829
8-Hydroxy-2-(di-N-propylamino) tetralin, 381
Hyperglycemia, 511
Hypophysectomy, 517
Hypothalamus, 879
Hypothermia, 1, 241

ICV administration, 325
Idazoxan, 89
Imipramine, 275
Impairment, 303
Inbred strains of mice, 375
Inbred strains of mice (BALB/cBy and C57BL/6By), 733
Inclined plane, 1
Incremental repeated acquisition, 29
Indirect calorimetry, 765
Ingestion, 919
Ingestive behavior, 387
Inhibition of RNA, 77
Inhibition of amine uptake, 165
Inhibitory amino acids, 491
Instructions, 149
Insulin, 539, 631, 765
Intake, 487
Interdrug associations, 1
Interoceptive stimulus control, 641
Intoxication, 905
Intrathecal administration, 491
Intrathecal morphine, 265
Intrathecal space, 107
Inverse agonist, 37, 733
In vivo catecholamine release, 879
Ipsapirone, 811, 927
Isobutylmethylxanthine, 705
Isocarboxazid, 283
Isolation stress, 915
Isolation-induced timidity, 361
Isoniazid, 399
Itch, 491

K-function, 863
Ketone bodies, 791

LSD, 571
LY 171555, 43, 193
LY163502, 453
Lateral preoptic area, 101
Learning, 29, 181
Learning and memory, 209, 649, 663
Lesions, 663
Lever-pressing, 275, 283
Levodopa, 193
Lick detectors, 419
Lidocaine, 887
Liquid diet, 919
Lithium, 591
Local anesthetics, 887
Locomotion, 739, 753, 779
Locomotor, 413
Locomotor activity, 101, 331, 345, 465, 507, 545, 785, 887
Lofexidine, 433
Long-term potentiation, 13
Lordosis, 665
Lordosis behavior, 89
*Lumbricus*, 213

MAO-B, 823
mCPP, 811
MDA, 571
MDMA, 223, 497, 571
MK-801, 13
$MPP^+$, 545
MPTP, 113, 545
MSLT, 321
Male sexual behavior, 53
Marihuana, 173, 521, 871
Maternal behavior, 83
Maturation, 413
Mecamylamine, 817
Mecamylamine prevention of nicotine lethality, 559
Medial preoptic area, 453
Memory, 29, 181, 823
Mental retardation, 759
Meperidine, 429
Methadone, 705
5-Methoxy-N,N-dimethyltryptamine (5-MeODNT), 603
N-methyl-D-aspartate receptors, 313
N-Methyl-4-phenyl-1-1,2,3,6-tetrahydropyridine (MPTP), 193
Methyl β-Carboline-3-carboxylate (β-CCM), 733
Mice, 17, 113, 129, 293, 317, 361, 553, 769, 779
Microdialysis, 899

Midazolam, 439
Midbrain central gray, 665
Milacemide, 823
Monetary reinforcement, 297
Monkeys, 29, 193, 433
Monoamine metabolism, 355
Monoamine metabolites, 341
Morphine, 83, 241, 361, 425, 429, 511, 705, 847, 911, 919
Morphine analgesic tolerance, 265
Morphine dependence, 595
Morphine tolerance, 445
Morphine tolerance-dependence, 7
Motion sickness, 317
Motivation, 871
Motor behavior, 685
Motor disturbances, 673
Mouse-killing behavior, 395
Movement disorder, 759
Multiple T-maze learning, 805
Muricide, 879
Muscarinic, 207
Muscle relaxation, 1
Muscular dystrophy, 681
Mycotoxin, 229
Myocardium, 247

NAN-190, 927
nBM lesion, 129
NMDA, 181, 739
NMDA receptor, 13, 649, 823
NMDA receptor antagonist, 739
N-0437, 17
$N^6$-(L-2-phenylisopropyl)-adenosine (L-PIA), 507
Naloxone, 197, 317, 425, 539, 753, 911
Naloxone-induced analgesia (NIA), 197, 425
Naloxone-precipitated withdrawal, 7
Naltrexone, 577
Naltrexone prevention of nicotine lethality, 559
*Nerodia*, 95
Neuroleptics, 95, 293, 655
Neurotoxicity, 223
Nicotine, 149, 261, 559, 565, 817
Nicotine's respiratory depressant actions in the rat, 559
Nicotinic receptor, 817
Nifedipine, 325, 915
Nociception, 911
Nonhuman primates, 685
Noradrenergic activity, 931
α-Noradrenergic antagonist, 553
Noradrenergic transmission, 89
Norepinephrine, 165, 247, 413
Nucleus accumbens, 101, 739, 899
Nursing mice, 229

Obesity, 255
Olfactory bulbectomy, 395, 879
Ondansetron, 769
One trial learning, 663
Operant, 65
Operant behavior, 29, 641, 923
Operant performance, 855
Operant responding, 927
Opiate analgesic synergy, 265
Opiate receptors, 425
Opiates, 83, 419, 753
Opioid receptors, 847
Opioid withdrawal, 705
Opioidergic and nicotinic processes: nicotine lethality, 559
Opioids, 83, 241
Oral movement, 43
Oral self-administration, 419
Organophosphates, 473
Oxotremorine, 207
Oxytocin, 673

Pain, 119, 911
Pain responses, 511
Parity, 83
Parkinsonism, 193, 759
Parkinson's Disease, 545
Passive avoidance, 181, 439
Pattern recognition, 863
Penile erection, 453, 673
Pentobarbital, 23, 49, 669, 915
Performance, 303, 321, 871
Performance effects, 173
Periaqueductal gray, 265
Pharmacological responses, 847
Phenelzine, 283
Phenoxybenzamine, 553
Phenylethylamines, 797
Phenylpropanolamine, 187
Phorbol ester, 665
Physical dependence, 49, 241, 919
Physostigmine, 915
Picrotoxin, 399
Pigeons, 59, 641
Pituitary, brain regions, 7
Placebo, 261
Plasma glucose, 255
Plus-maze, 1, 313
Polydipsia, 691
Position preference, 419
Position responding, 641
Postejaculatory vocalization, 53
Postero-median nucleus accumbens, 157
Potassium stimulation, 107
Prazosin, 89
Preference, 297
Prenatal drug effects, 721, 727
Prenatal-postnatal exposure, 229
Progesterone, 89
Progressive ratio, 29
Prolactin, 83
Protein, 829
Protein kinase C, 665
Protein metabolism, 77
Psychomotor, 303
Psychomotor stimulants, 655
Psychomotor tasks, 173
Puffing behavior, 631
Push-pull perfusion, 879
Push-pull superfusion, 107

QNB binding, 129
Quasiopioid withdrawal, 705
Quinelorane, 453

REM, 37, 507
RO 15-1788, 197, 585, 839
RO 15-4513, 23, 585, 785
RU 24969, 811
Rabbit, 325, 433
Radial arm maze, 13, 599
Radioimmunoassay, 747
Raphe lesions, 395
Rapid information processing, 631
Rat, 17, 49, 53, 119, 157, 181, 207, 209, 261, 337, 345, 349, 355, 387, 429, 465, 511, 533, 585, 599, 619, 711, 765, 769, 817, 855, 863, 919
Rat masculine sexual behaviour, 811
Rat vas deferens assay, 527
Rats, female, 491
Receptors, 207, 261
Recreational activity, 871
Reference memory, 599
Regional superfusion, 107
Reinforcement, 59, 149, 899
Renin-angiotensin system, 201
Renovascular hypertension, 685
Respiratory effects, 405
Respiratory quotient, 765
Responses to hypercapnia, 681
Resting behavior, 387
Restraint stress, 517
Reuptake, monoamine, 887
Rhesus monkeys, 521, 669
Ritanserin, 533
Rotation, 663
Rotation behavior, 139

SCH 23390, 43, 113, 337, 367
SKF 38393, 17, 43, 367
SKF 38393-inducible RJM in control and EEDQ-treated rats, 895
SK&F 75760, 17
Saliva, 483, 747
Satiety, 829
Sclareol glycol, 503
Scopolamine, 599
Scratching, 491
Secalonic acid, 229
Secobarbital, 609, 669
Sedation, 507
Seizures, 733
Seizures, cocaine-induced, 887
Seizures, lidocaine-induced, 887
Selected lines, 399, 905
Selected lines of mice, 375
Selective dopamine receptor agonists and antagonists, 53
Self-administration, 187, 669, 899
Seminal emission, 453
Sensitization, 59, 465, 655
Sensorimotor behavior, 113
Sensory-evoked potentials, 619
Sensory stimulation, 107
Septum, 553
Serotonin, 341, 367, 413, 497, 571
Serotonin hyperinnervation, 367
Serotonin receptors, 595
Serotonin syndrome, 367
Serum insulin, 255
Serum triglycerides, 255
Sexual behavior, 89
Sham lesion, 915
Shock, 591
Sleep, 37, 507, 533
Sleepiness, 321
Smoking, 149, 631
Smoking topography, 173
Social behavior, 609
Social behavioral deficit, 293
Social interaction, 297
Solvent abuse, 619
Soman, 473
Spatial navigation, 129
Spinal cord, 107
Spinal opiate antinociception, 445
Spinal rats, 445

Spiroxatrine, 381
Stereoisomers, 669
Stereotypy, 545, 727
Stress, 207, 261, 317, 349
Stress adaptation, 603
Stress-induced analgesia, 197
Stress ulceration, 73
Striatum, 139, 459
Structure-activity relationship, 527
Subfornical organ, 201
Subjective effects, 173, 697, 791
Substance P, 491, 527
Substance P receptors, 527
Substantia innominata, 101
Sucrose, 911
Sulpiride, 43, 113
Supersensitivity, 113, 545
Sweeteners, 483
Symbolic, matching-to-sample, 641

$T_4$, $T_3$, $T_3U$, TSH, 7
TFMPP, 811
THC, 173
TRH, 95
TRH receptors, 7
Tail flick, 265
Tail-flick test, 497
Tail-tremor, 817
Taste, 419, 483
Taurine, 491
Telemetry, 261
Temporal response differentiation, 29
Test battery, 29
Thermogenesis, 765
Thermoregulation, 241, 261, 325, 539
Thyroid hormones, 7
Time-course, 289
Tizanidine, 433
Tobacco, 149
Tolerance, 59, 149, 331, 465, 473, 855, 911
Trazodone, 275
Triglycerides, 631
Tryptophan, 829
Type A CCK receptors, 779
Vacuous chewing movement, 43
Vasoactive intestinal peptide, 387
Vasopressin, 673
Verapamil, 73, 325

Wakefulness, 533
Water intake, 797
Weight gain, 691
Withdrawal, 911, 931
Withdrawal signs, 839
Withdrawal syndrome, 49, 241
Working memory, 13, 553, 599

*Xenopus* skin mucus, 95
Xenopsin, 95
Xylamidine, 717

YM-09151-2, 355
Yawning, 95, 237, 673, 915

## AUTHOR INDEX

Advokat, C., 265, 445
Ågmo, A., 811
Ali, S. F., 721, 727
Alkana, R. L., 375
Alvarez, W. F., 759
Araki, Y., 817
Argiolis, A., 673
Arnolde, S. M., 823
Asai, S., 355
Atrens, D. M., 765

Babbini, M., 429
Babcock, A. M., 539
Bacchi, A., 429
Baldwin, H. A., 931
Banas, C., 491
Bansinath, M., 7
Barfield, R. J., 53
Barthalmus, G. T., 95
Bartoletti, M., 429
Barton, C., 539
Baruch, N. P., 663
Bättig, K., 631
Beau, N., 157
Bejanian, M., 375
Belknap, J. K., 241
Benarroch, A., 487
Beninger, R. J., 923
Benowitz, N. L., 565
Berman, K. F., 507
Bernstein, D. J., 871
Berridge, C. W., 517
Bettin, M. A., 317
Beyer, C., 491
Bhargava, H. N., 7
Bickel, W. K., 297
Bitran, D., 453
Blundell, J. E., 829
Bodnar, R. J., 119, 511
Boggan, W. O., 331
Boja, J. W., 497
Bolon, B., 229
Bostwick, M., 559
Bosy, T. Z., 165
Bourson, A., 915
Brady, J. V., 871
Brake, L. D., 1
Breese, G. R., 367
Bridges, R. S., 83
Britton, D. R., 779
Bronson, M. E., 705
Brown, C. R., 565
Bruno, J. P., 113
Burg, B., 59
Burris, K., 571
Butelman, E. R., 13

Cagiano, R., 53
Calderon, S. F., 545
Cappell, H., 197, 425
Carelli, R. M., 739
Carlson, K. R., 419
Castellano, C., 361
Chan, A. W. K., 839
Chapouthier, G., 733
Cherek, D. R., 65
Cho, C. H., 73
Cohen, Y., 341, 577
Collins, A. C., 887
Connelly, D. M., 255
Cook, J. M., 37
Cook, V. I., 387
Cooper, M. L., 119
Cooper, S. J., 17
Cordi, A. A., 649, 823
Costall, B., 769
Cottrell, G. A., 459
Coyle, J. T., 129
Crisp, T., 497
Criswell, H. E., 367
Cullen, M. J., 779
Cuomo, V., 53

D'Amato, F. R., 361
Das, S., 7
Daugé, V., 157
Dave, V., 275
Deans, C., 927
de Fiebre, C. M., 887
Delius, J. D., 59
DeNoble, V. J., 181
Derrien, M., 157
Desforges, C., 733
Deviche, P., 753
de Wit, H., 791
Dilsaver, S. C., 207, 261
Dodd, R. H., 733
Doger, E., 237
Double, K., 691
Doyle, J. S., 387
Dugovic, C., 533
Dunn, A. J., 517
Durkin, T., 553

Edwards, S., 717
Eguibar, J. R., 237
El-Etri, M. M., 545
Ellman, G., 759
Eriksson, P. S., 919
Escalante, A., 811

Favara, J. P., 331
Feder, H. H., 89
Féger, J., 157
Fenwick, J. W., 149
Fernandez-Guasti, A., 811
File, S. E., 931
Finn, D. A., 375
Fischman, M. W., 871
Flemmer, D. D., 207, 261
Foderaro, M. A., 387
Foltin, R. W., 871
Frances, H., 293
Friedhoff, A. J., 895
Fujiwara, M., 879
Furuno, K., 817

Gaiardi, M., 429
Galizio, M., 585
García-Antón, J. M., 527
Gardner, C. R., 711
Geary, N., 797
Georgieva, J. V., 503
Gessa, G. L., 673
Gibson, J. E. M., 487
Gilbert, D. B., 439
Giordano, M., 139
Glazner, G. W., 387
Gomita, Y., 817
Gonzalez-Flores, O., 491
Goudie, A., 927
Goudreau, J., 283
Gough, B. J., 721
Grupp, L. A., 201
Gubellini, C., 429
Gulliver, S. B., 149

Haase, C., 59
Hadjiconstantinou, M., 113
Hagen, T. J., 37
Halpern, M., 213
Hamm, M. W., 247
Handelmann, G. E., 649, 823
Haro, I., 527
Harris, N., 349
Hasenfratz, M., 631
Heishman, S. J., 173
Hellevuo, K., 399, 905
Hellhammer, D. H., 747
Henningfield, J. E., 303
Hienz, R. D., 685
Higgins, S. T., 149, 297, 303, 609
Hines, G., 591
Hitchcott, P. K., 931
Ho, I. K., 847
Hoffman, A. J., 571
Hoffman, D. C., 923
Holloway, F. A., 855
Holmgren, B., 237
Holson, R. R., 721, 727
Hood, W. F., 649
Hopper, D. L., 863
Horan, P. J., 847
Hughes, J. R., 149, 297
Hull, E. M., 453

Imamura, Y., 355
Ishihara, T., 805
Ishii, Y., 355
Ishikawa, K., 355
Iversen, S. D., 465
Iwasaki, K., 879

Jackson, B., 313
Jacquot, C., 341, 577
Jaffard, R., 553
Jaffe, J. H., 697
Jammers, W., 747
Janssen, P. F. M., 533
Jarrard, L. E., 599
Jarvis, M. F., 739
Jiang, X. C., 213
Joh, T. H., 367
Johnson, M. P., 571
Jones, B. J., 769
Jones, B. L., 375
Jones, K. W., 181
Jordan, F., 107
Justice, J. B., Jr., 899

Kamei, J., 595
Kamien, J. B., 337
Kasuya, Y., 595
Katz, N. L., 433
Kavaliers, M., 317
Keene, T., 539
Kelly, M. E., 769
Kelly, T. H., 65, 871
Kepler, K. L., 119
Kernan, W. J., Jr., 863
Kerwin, J. F., Jr., 779
Kest, B., 119
Kiefel, J. M., 119
Kiianmaa, K., 399, 905
King, D., 149, 855
Kinsley, C. H., 83
Kirschbaum, C., 747
Knoke, D. M., 197
Komisaruk, B. R., 107, 491
Koo, M. W. L., 73
Kopecka, H., 779
Korpi, E. R., 399
Krieman, M., 349
Kubo, T., 355
Kulkosky, P. J., 387
Kumor, K. M., 697

Lamb, R. J., 303
Langan, M. C., 839
Lauder, J. M., 367
Lê, A. D., 197, 425
Leathley, M., 927
Lebrun, C., 553
Leong, F. W., 839
Levin, E. D., 43
Leysen, J. E., 533
Li, T.-K., 381
Liebman, J. M., 739
Lienard, C., 293
Lindenblatt, U., 59
Lowry, C. A., 753
Lubin, E., 511
Lumeng, L., 381

McBride, W. J., 381
McMillan, D. E., 641
Mackenzie-Taylor, D., 275, 283
Mann, P. E., 83
Marighetto, A., 553
Martin-Iverson, M. T., 465
Martin, J. V., 37, 507
Martin, R. J., 911
Martin, W. R., 405, 559
Masters, D. B., 107
Matteucci, M. J., 619
Matthies, H., 209
Mattingly, B. A., 345
Maynard, E. H., 367
Mela, D. J., 483
Melis, M. R., 673
Mendelson, W. B., 37, 507
Menéndez, J. A., 765
Metz, T. J., 681
Meyer, M. E., 459
Michael, R. P., 23, 785
Middaugh, L. D., 331
Mikuni, M., 603
Mireault, G., 149
Mobbs, C. V., 665
Monahan, J. B., 649
Moore, F. L., 753
Mori, T., 595
Moser, P. C., 915
Mueller, L. L., 823
Mueller, R. A., 367
Mullenix, P. J., 863
Muntaner, C., 697
Murman, D., 655
Murphy, J. M., 381

Nadzan, A. M., 779
Nagoshi, C., 697
Nakamura, S., 805
Naylor, R. J., 769
Nellis, M. J., 871
Nevins, M. E., 823
Nichols, D. E., 223, 571
Norman, A. B., 139, 545

Oakley, N. R., 769
Oberlender, R., 571
Ogawa, M., 595
Ogle, C. W., 73
Ohi, K., 603
Ohno, M., 395
Okaichi, H., 599
Onaivi, E. S., 769
O'Neill, K. A., 739
Orosco, M., 341, 577
Oshima, Y., 599
Ossenkopp, K.-P., 317
Overstreet, D. H., 691

Palmi, M., 325
Pappas, B. A., 413
Patterson, T. A., 439
Paule, M. G., 29, 641
Pellaud, K., 631
Penetrante, M. L., 839
Perlanski, E., 201
Pert, A., 655
Peterson, C. S., 89
Peterson, J. T., 247
Pettit, H. O., 899
Pfaff, D. W., 665
Pfiffner, D., 631
Pleim, E. T., 53
Pohorecky, L. A., 247
Popov, N., 209
Post, R. M., 655
Poulos, C. X., 197, 425
Prasad, R., 7
Pryor, G. T., 521, 619
Puttfarcken, P. S., 129

Rawat, A. K., 77
Rebert, C. S., 521, 619
Rech, R. H., 275, 283
Reig, F., 527
Riechert, U., 209
Roane, D. S., 911
Robert, J. J., 341, 577
Rockman, G. E., 487
Rodriguez, R. E., 527
Roehrs, T., 321
Rönnbäck, L., 919
Ronsheim, P. M., 83
Roques, B. P., 157
Rose, S. P. R., 439
Rosengarten, H., 895
Rosofsky, M., 797
Roth, T., 321
Rothfeld, J. M., 665
Roubertoux, P. L., 733
Rouch, C., 341, 577
Rowlett, J. K., 345
Ruiz, P., 527
Rusk, I. N., 17
Ruth, J. A., 165, 887

Sachs, B. D., 453
Saluja, R., 665
Sanberg, P. R., 139, 545
Sanchez, J., 433
Scalzo, F. M., 721, 727
Schaefer, G. J., 23, 785
Schaeffer, C. L., 181
Schanley, D. L., 839
Schechter, M. D., 289, 497
Schenk, S., 187
Schiller, G. D., 691
Schlemmer, R. F., Jr., 433
Schlenker, E. H., 681
Schneider, J. S., 193
Schoenbaum, G. M., 911
Schultz, K. A., 663
Schulze, G. E., 29
Schweitzer, J. W., 895
Sebastian, C. S., 65
See, R. E., 43
Sgaragli, G., 325
Sharma, A., 77
Shelton, K., 187
Shibanoki, S., 355
Shipley, M. T., 545
Shreve, P. E., 101
Shukla, R., 275, 283
Silverman, P. B., 663
Siuciak, J. A., 265, 445
Skolnick, P., 313, 507
Slikker, W., Jr., 29
Sloan, J. W., 559
Smythe, J. W., 413
Sobaski, N., 433
South, D., 43
Sparber, S. B., 705
St. Omer, V. E. V., 229
Stafinsky, J. L., 497
Stancampiano, R., 673
Steele, T. D., 223
Steimes, P., 157
Steinberg, J. L., 65
Stevens, R. G., 717
Stewart, R. B., 201
Stitzer, M. L., 173, 609
Stone, R. K., 759
Strasburger, C. J., 747
Strickler, G., 149
Suemaru, K., 817
Sweeney, J. E., 129
Syapin, P. J., 375

Taberner, P. V., 255
Tada, K., 355
Takahashi, K., 603
Taukulis, H. K., 1
Taylor, J., 349
Teff, K. L., 829
Thompson, J. T., 453
Thornton, J. E., 89
Timms, V., 321
Toffano, G., 209
Toumane, A., 553
Towle, A. C., 367
Trullas, R., 313
Turkkan, J. S., 685
Tyers, M. B., 769

Ueki, S., 395, 879
Urbá-Holmgren, R., 237
Uretsky, N. J., 101

Valencia, G., 527
van Dongen, C. J., 473
Van Hartesveldt, C., 459
Vanover, K. E., 669
Venault, P., 733
Vincent, P. A., 89
Vogel, W. H., 349

Wang, D., 213
Wauquier, A., 533
Weihmuller, F. B., 113
Weiss, S. R. B., 655
Weissman, E. M., 545
Wellman, P. J., 187
Wenger, G. R., 641, 669
Wessinger, W. D., 641
White, N. R., 53
Wolthuis, O. L., 473
Woodward, R., 655
Woolverton, W. L., 337, 669
Wu, K.-M., 405

Yahiro, L., 779
Yamamoto, T., 395
Yatsugi, S.-I., 395
Yim, G. K., 223
Yingling, J. E., 173
Young, J. E., 433
Young, S. N., 829
Yutrzenka, G. J., 49

Zacny, J. P., 791
Zorick, F., 321
Zubrycki, E. M., 545
Zwyghuizen-Doorenbos,A.,321